Literature DB >> 11012164

T lymphocytes determine the development of xeno GVHD and of human hemopoiesis in NOD/SCID mice following human umbilical cord blood transplantation.

S F Verlinden1, A H Mulder, J P de Leeuw, D W van Bekkum.   

Abstract

Over the past decade the human-immunodeficient mouse chimera has become a well-established in vivo model for studying the human immune system and/or hemopoiesis. Under certain experimental conditions and depending on the composition of the human cell graft, the recipient mice may develop a fatal disease, designated as discordant xenogenic graft-versus-host-disease (GVHD), which differs in target tissues and histopathology from allogenic GVHD. Experimental evidence is presented that immunodeficient mice are equally susceptible to allogenic GVHD as normal immunocompetent mice. Whole human cord blood and distinct cellular subpopulations from a single cord blood harvest were transplanted in NOD/severe combined immunodeficient mice and the repopulation of human cells was monitored over time. Depending on the ratio of lymphocytes to hemopoietic stem cells, proliferation of human T cells, hemopoiesis or a combination of the two is observed in widely varying proportions. When the graft contains a preponderance of lymphocytes, fatal protracted discordant xenogenic GVHD develops. Mice receiving purified CD34 cells survived up to 207 days in good health with more than 95% human cells in the bone marrow. In those mice all lineages (B and T lymphocytes, monocytes, granulocytes, erythrocytes and thrombocytes) were demonstrated in the bone marrow and peripheral blood.

Entities:  

Mesh:

Year:  1998        PMID: 11012164     DOI: 10.1002/stem.5530160825

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  8 in total

Review 1.  Immune modulation of inflammatory conditions: regulatory T cells for treatment of GvHD.

Authors:  Doreen Haase; Mireille Starke; Kia Joo Puan; Tuck Siong Lai; Olaf Rotzschke
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

2.  Update of humanized animal disease models in studying Graft-versus-host disease.

Authors:  Feng Huang; Feng Lin Cao; Song Guo Zheng
Journal:  Hum Vaccin Immunother       Date:  2018-09-05       Impact factor: 3.452

3.  Immunoregulation of a CB2 receptor agonist in a murine model of neuroAIDS.

Authors:  Santhi Gorantla; Edward Makarov; Deepa Roy; Jennifer Finke-Dwyer; L Charles Murrin; Howard E Gendelman; Larisa Poluektova
Journal:  J Neuroimmune Pharmacol       Date:  2010-06-12       Impact factor: 4.147

4.  Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease.

Authors:  Simrit Parmar; Xiaoying Liu; Shawndeep S Tung; Simon N Robinson; Gabriel Rodriguez; Laurence J N Cooper; Hui Yang; Nina Shah; Hong Yang; Marina Konopleva; Jeffery J Molldrem; Guillermo Garcia-Manero; Amer Najjar; Eric Yvon; Ian McNiece; Katy Rezvani; Barbara Savoldo; Catherine M Bollard; Elizabeth J Shpall
Journal:  Cytotherapy       Date:  2013-10-26       Impact factor: 5.414

Review 5.  Human hemato-lymphoid system mice: current use and future potential for medicine.

Authors:  Richard A Flavell; Markus G Manz; Anthony Rongvaux; Hitoshi Takizawa; Till Strowig; Tim Willinger; Elizabeth E Eynon
Journal:  Annu Rev Immunol       Date:  2013-01-16       Impact factor: 28.527

6.  Graft versus host disease in the bone marrow, liver and thymus humanized mouse model.

Authors:  Matthew B Greenblatt; Vladimir Vrbanac; Vladimir Vbranac; Trevor Tivey; Kelly Tsang; Andrew M Tager; Antonios O Aliprantis
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240

7.  In vivo expansion of co-transplanted T cells impacts on tumor re-initiating activity of human acute myeloid leukemia in NSG mice.

Authors:  Malte von Bonin; Martin Wermke; Kadriye Nehir Cosgun; Christian Thiede; Martin Bornhauser; Gerard Wagemaker; Claudia Waskow
Journal:  PLoS One       Date:  2013-04-09       Impact factor: 3.240

8.  Immune humanization of immunodeficient mice using diagnostic bone marrow aspirates from carcinoma patients.

Authors:  Melanie Werner-Klein; Judith Proske; Christian Werno; Katharina Schneider; Hans-Stefan Hofmann; Brigitte Rack; Stefan Buchholz; Roman Ganzer; Andreas Blana; Birgit Seelbach-Göbel; Ulrich Nitsche; Daniela N Männel; Christoph A Klein
Journal:  PLoS One       Date:  2014-05-15       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.